Inclusion Criteria:

1. Signed and dated informed consent by the patient or the patient's Legally Acceptable Representative (LAR)
2. Age ≥18 years old at time of diagnosis of R/R-DLBCL
3. Histologically confirmed diagnosis of DLBCL according to World Health Organization (WHO) classification, including histologically confirmed diagnosis of high-grade lymphoma with double and triple hit: DLBCL with MYC and BCL2/BCL6 translocation (double-hit) and MYC and BCL2 and BCL6 translocations (triple-hit)
4. Availability of data on first-line (and second-line, if applicable) DLBCL therapy (with the minimum data required including treatment type, number of cycles and response)
5. Relapsed or refractory DLBCL after at least one prior systemic therapy, and prior to second- or third-line therapy for DLBCL (previous treatment can include ASCT)
6. Not planning to receive HD-ASCT at enrolment

Exclusion Criteria:

1. Concurrent participation in an interventional clinical study
2. Receiving ASCT therapy (note: having received ASCT in the past is not an exclusion criterion)